The International Severe Acute Respiratory Infection Coronavirus Clinical Characterisation Consortium (ISARIC 4C) is a UK-wide consortium of doctors and scientists committed to answering urgent questions about COVID-19. The ISARIC Clinical Characterisation Protocol (CCP) aims to study COVID-19 disease to better understand its spread and behaviour by analysing biological samples and data from patients with confirmed […]

Clinical characteristics and outcomes for hospitalised COVID-19 patients in the UK are important to guide the national response to this pandemic and emerging evidence suggests ethnic minorities might be disproportionately affected. Imperial researchers undertook a retrospective cohort study to characterise the main risk factors associated with in-hospital deaths on patients hospitalised with laboratory-confirmed SARS-CoV-2 infection […]

Convalescent plasma is the antibody-rich plasma of someone who has recovered from a virus. The plasma may contain antibodies that their immune system has produced in fighting the virus – in this case, COVID-19, which can then be transfused into infected patients whose immune systems are struggling to fight the infection. The REMAP-CAP trial is […]

Established in 2013, and part of Imperial College London, the NIHR London In Vitro Diagnostics has a strong track record working with innovators to enable evidence generations, supporting market adoption. They do this by working closely with clinicians within healthcare settings and through partnerships with world-class technologists, scientists and methodologists. In response to the COVID-19 […]

Imperial’s Clinical Analytics, Research and Evaluation (iCARE) project started as a proof of concept high performance analytics environment, funded by NIHR Imperial BRC, in Autumn 2019. In collaboration with UKCloud and Bluemetrix, the NIHR Imperial BRC have set up a high performance, cloud-based, informatics solution that will allow NHS Trust staff to access de-identified data […]